Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Top Cited Papers
- 16 July 2004
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 305 (5682) , 399-401
- https://doi.org/10.1126/science.1099480
Abstract
Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding. Crystallographic studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements. BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants. BMS-354825 prolongs survival of mice with BCR-ABL–driven disease and inhibits proliferation of BCR-ABL–positive bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML. These data illustrate how molecular insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.Keywords
This publication has 17 references indexed in Scilit:
- High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinibThe Hematology Journal, 2004
- A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeNew England Journal of Medicine, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate–resistant Bcr-Abl kinasesBlood, 2003
- Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyLeukemia, 2002
- Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatmentBlood, 2002
- BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective studyThe Lancet, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996